• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Chennai, July 10

Shasun Chemicals & Drugs Ltd today announced that its wholly owned UK subsidiary Shasun Pharma Solutions Ltd has entered into a non-exclusive licensing agreement with H Lundbeck A/S, a research-based Danish company engaged in finding new drugs for treatment of CNS (Central Nervous System) disorders. As per the agreement, Shasun Pharma grants H Lundbeck A/S the use of its proprietary cross-coupling technology (also known as Buchwald technology) to manufacture and comme rcialise new APIs (active pharmaceutical ingredients). Commenting on the development, Dr Michel Spagnol, Vice-President, Lundbeck, said, “Lundbeck will have access to one of the most powerful cross-coupling technologies allowing them to speed up the development of new drugs while reducing the cost of manufacture.” —

Our Bureau

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Coal India move to fight corruption in procurement

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line